ATG-F VS ATG for the Prevention of GVHD

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Anti-thymocyte globulin (ATG) preparative regimen in the setting of haploidentical stem cell transplantation (haplo-HSCT) is vital for inducing immune tolerance.The study aims to compare the efficacy and safety of ATG-F vs ATG, incorporated into the preparative regimens for haplo-identical transplants.

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Fujian Medical University
• Treatments: Immunosuppressive Agents

Criteria

Inclusion Criteria:

• Signed written informed consent

• Aged <65 years

• Patients undergoing Haplo-identical hematopoietic stem cell transplantation.

• Cardiac: Left ventricular ejection fraction ≥ 50%

• Adequate renal and hepatic function

• Performance status: Karnofsky ≥ 70%

Exclusion Criteria:

• Pregnant or lactating females.

• Any co-morbidity precluding the administration of ATG or ATG-F.